IGI Logo
Toggle Navigation
News
Hindi
Hindi News
Top News
Screeners
Stocks
Stocks Screener
Stock
News
Stock Market Home Page
Stock News
Industry News
Economy News
Stock on the move
Expert Views
Research Reports
Company Result
Comp Info And Fundamentals
Company Profile
Equity
Financial Ratios
Results
Balance Sheet
Profit And Loss
Cash Flow
Share Holding
Derivatives (F&O)
Get Quotes
Market Watch
Top Gainers
Top Losers
Top Traded Quantity
Top Traded Value
Most Active Puts
Derivatives (F&O)
Most Active Calls
Put Call Ratio
Highest In Premium
Daily Settlement Price
FII and DII Statistics
Open Interest: Highest In OI
Open Interest: Lowest In OI
Derivatives (F&O)
Open Interest: Increase in OI Increase in Price
Open Interest: Decline in OI Decrease in Price
Derivative Watch
Derivatives Dashboard
Historical Data
List of Underlyings & Underlying Info
Derivative Watch
Derivatives Dashboard
Market Reports
Top Gainers
Top Losers
Monthly High/Low
52 Week High
52 Week Low
Market Cap Gainers
Market Cap Losers
PE Ratio
>More Market Reports
IPO
News
IPO News
IPO Issue Reports
Commodity
Commodity Market
Commodity Home Page
Commodity News
Commodity Reports
Market Details
Get Quotes
Top Gainers
Top Losers
Top Volume
Top Value
Top Gainers Spot Market
Top Losers Spot Market
High & Low
Commodity Indices
Technical Analysis
Advance Declines
High & Low
Highest In OI
Lowest OI
Increase In Open Interest(%)
Descrease In Open Interest(%)
Currency
News
Currency News
Economy News
Currency Reports
Mutual Fund
News
Mutual Fund Home Page
Mutual Fund News
Mutual Fund Details
Mutual Fund Home Page
Compare Scheme
Scheme Profile
Mutual fund Investment
Mutual Fund Share Holding
Mutual Fund Statistics
Mutual fund Gainers
Mutual fund Losers
Biggest Schemes
Best Performers
Latest Dividend Details
Tools
Multi Scheme Comparison Tool
Dividend Details
Performance Map
Mutual fund Investment
Mutual fund Share Holding
Mutual Fund Search Category Rankings
Widgets
Stock Widgets
Watchlist
Heatmap
Mutual Fund Widgets
Watchlist
Calculators
EMI Calculator
SIP Calculator
SWP Calculator
GST Calculator
FD Calculator
RD Calculator
Wealth
World
Tips
Intraday Tips
Market Outlook
Stock Tips
Commodity Tips
Currency Tips
Reports
Short Term Investment Opportunities
Long Term Investment Opportunities
Sector Analysis
Commodity Reports
Currency Reports
Mutual Fund Analysis
Podcast
Videos
Videos Category
Business Videos
Budget Videos
News And Politics
Entertainment Videos
Sports Videos
Lifestyle And Fashion Videos
Global News Videos
Calculators
EMI Calculator
SIP Calculator
SWP Calculator
GST Calculator
FD Calculator
RD Calculator
More
Budget 2024
Astrology
Women
Politics
Entertainment
Car&Bike
Gadgets
Lifestyle
Sports
Health
Fashion
Diwali Reports
Diwali Expert Reports
News
Astrology
Beyond Market Car
Beyond Market Entertainment
Beyond Market Fashion
Beyond Market Gadgets
Beyond Market Health
Beyond Market India
Beyond Market Life Style
Beyond Market Sports
Broking Firm Views
Broking Firm Views - Long Term Report
Broking Firm Views - Sector Report
Broking Firm Views - Short Term Report
Budget 2024 Sector Reports
Budget Bites
Budget Economic Servey
Budget Expert Views
Budget Industry
Budget News
Budget Wishlist
Commodities
Commodities Reports
Commodity Top News
Company News
Company Result
Currency News
Currency Report
Currency Top News
Diwali Expert Views
Diwali Market Outlook
Diwali Report
Diwali Technical Report
Economy News
Expert View Institution
Expert Views
Industry News
IPO Analysis
IPO More News
IPO Reports
IPO Top News
Market Outlook
Mutual Fund Analysis
Mutual Fund Expert Views
Mutual Fund More News
Mutual Fund Top News
Podcast - Market Ki Awaaz
Special Event Expert Views
Special Event Reports
Startup
Startup Expections
Startup Speak
Stock Market
Stock On The Move
Top News
Top Stories
Videos
Videos Business
Videos Entertainment
Videos Global News
Videos Lifestyle And Fashion
Videos News And Politics
Videos Sports
Wealth
Women
World Market More News
World Top News
Search
Indian drugmaker Zydus Lifesciences reported a 14% rise in second-quarter profit on Tuesday, helped by strong demand for generic drugs in its key United States and Indian markets. The company's consolidated net profit rose to 9.11 billion rupees ($107.93 million), in line with analysts' average estimate of 9.13 billion rupees, as per data compiled by LSEG. Its total revenue climbed 20% to 52.37 billion rupees, boosted by a nearly 30% growth in its U.S. market and a 10% climb in ...
India`s Zydus Life posts Q2 profit rise on steady US demand
Zydus Lifesciences is currently trading at Rs. 1015.00, up by 26.80 points or 2.71% from its previous closing of Rs. 988.20 on the BSE. The scrip opened at Rs. 981.05 and has touched a high and low of Rs. 1016.35 and Rs. 981.05 respectively. So far 33456 shares were traded on the counter. The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 1323.90 on 09-Aug-2024 and a 52 week low of Rs. 567.85 on 26-Oct-2023. Last one week high and low of the scrip s...
Zydus Lifesciences jumps on getting in principle acceptability from WHO for ZyVac TCV
Zydus Lifesciences is currently trading at Rs. 1022.85, up by 1.95 points or 0.19% from its previous closing of Rs. 1020.90 on the BSE. The scrip opened at Rs. 1025.05 and has touched a high and low of Rs. 1028.00 and Rs. 1013.95 respectively. So far 4727 shares were traded on the counter. The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 1323.90 on 09-Aug-2024 and a 52 week low of Rs. 567.85 on 26-Oct-2023. Last one week high and low of the scrip ...
Zydus Lifesciences inches up on getting USFDA`s approval for Fludrocortisone Acetate Tablets
Zydus Lifesciences is currently trading at Rs. 1062.75, up by 5.75 points or 0.54% from its previous closing of Rs. 1057.00 on the BSE. The scrip opened at Rs. 1062.00 and has touched a high and low of Rs. 1064.15 and Rs. 1052.00 respectively. So far 67192 shares were traded on the counter. The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 1323.90 on 09-Aug-2024 and a 52 week low of Rs. 567.85 on 26-Oct-2023. Last one week high and low of the scrip...
Zydus Lifesciences gains on getting USFDA`s final approval for Paliperidone Extended-Release Tablets
Zydus Lifesciences is currently trading at Rs. 1080.90, up by 12.55 points or 1.17% from its previous closing of Rs. 1068.35 on the BSE. The scrip opened at Rs. 1076.95 and has touched a high and low of Rs. 1081.30 and Rs. 1063.00 respectively. So far 10411 shares were traded on the counter. The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 1323.90 on 09-Aug-2024 and a 52 week low of Rs. 567.85 on 26-Oct-2023. Last one week high and low of the scri...
Zydus Lifesciences trades higher on the BSE
Zydus Lifesciences gains on getting USFDA’s final approval for Scopolamine Transdermal System Aug-30-2024 14:08 Hrs IST Zydus Lifesciences is currently trading at Rs. 1145.55, up by 13.30 points or 1.17% from its previous closing of Rs. 1132.25 on the BSE. The scrip opened at Rs. 1140.00 and has touched a high and low of Rs. 1159.00 and Rs. 1128.95 respectively. So far 155881 shares were traded on the counter. The BSE group 'A' stock of face value Rs. 1 h...
Zydus Lifesciences gains on getting USFDA’s final approval for Scopolamine Transdermal System
Zydus Lifesciences is currently trading at Rs. 1134.20, up by 20.35 points or 1.83% from its previous closing of Rs. 1113.85 on the BSE. The scrip opened at Rs. 1147.05 and has touched a high and low of Rs. 1156.45 and Rs. 1128.05 respectively. So far 38036 shares were traded on the counter. The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 1323.90 on 09-Aug-2024 and a 52 week low of Rs. 567.85 on 26-Oct-2023. Last one week high and low of the scri...
Zydus Lifesciences surges on getting final nod to market Amantadine extended-release capsules
Indian drugmaker Zydus Lifesciences reported a bigger-than-expected first-quarter profit on Friday, driven by strong demand for its generic respiratory drugs in its key market of North America. The company's consolidated net profit jumped nearly 31% year-on-year to 14.2 billion rupees ($169.2 million) in the quarter ended June 30, beat analysts' average estimate of 12.34 billion rupees, per LSEG data. KEY CONTEXT Indian generic drugmakers earn a major chunk of their revenue f...
India's Zydus Lifesciences Q1 profit beats estimates on strong US demand
Zydus Lifesciences is currently trading at Rs. 1163.60, up by 19.00 points or 1.66% from its previous closing of Rs. 1144.60 on the BSE. The scrip opened at Rs. 1139.80 and has touched a high and low of Rs. 1165.45 and Rs. 1122.00 respectively. So far 8396 shares were traded on the counter. The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 1203.20 on 11-Jul-2024 and a 52 week low of Rs. 564.05 on 25-Jul-2023. Last one week high and low of the scrip...
Zydus Lifesciences soars on getting nod to market Bhava to treat various cancers
Zydus Lifesciences is currently trading at Rs. 1160.15, down by 25.15 points or 2.12% from its previous closing of Rs. 1185.30 on the BSE. The scrip opened at Rs. 1165.00 and has touched a high and low of Rs. 1168.75 and Rs. 1151.00 respectively. So far 89918 shares were traded on the counter. The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 1203.20 on 11-Jul-2024 and a 52 week low of Rs. 564.05 on 25-Jul-2023. Last one week high and low of the sc...
Zydus Lifesciences falls after USFDA classifies its`Jarod unit as `official action indicated`
Zydus Lifesciences is currently trading at Rs. 1181.15, up by 0.75 points or 0.06% from its previous closing of Rs. 1180.40 on the BSE. The scrip opened at Rs. 1199.45 and has touched a high and low of Rs. 1203.20 and Rs. 1176.35 respectively. So far 26907 shares were traded on the counter. The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 1,203.20 on 11-Jul-2024 and a 52 week low of Rs. 564.05 on 25-Jul-2023. Last one week high and low of the scri...
Zydus Lifesciences inches up on getting USFDA`s final approval for Sacubitril and Valsartan Tablets
Niche products, superior execution boost earnings Levers in place to improve business prospects over next 2-3 years * Zydus Life (ZYDUS) delivered a better-than-expected 4QFY24 performance, driven by increased off-take in the US/EU/API segments. ZYDUS saw better growth than the industry in the domestic formulation (DF) market. It ended FY24 on a strong note with 13%/41%/65% YoY growth in revenue/EBITDA/PAT. * We raise our earnings estimates by 12%/14% for FY25/FY26 to factor in a) ni...
Neutral Zydus LifeSciences Ltd. For Target Rs. 1,045 By Motilal Oswal Financial Services
Guidance smashes the sceptics Convincing beat in Q4 Zydus Lifesciences’ (ZYDUSLIF IN) Q4FY24 revenue and EBITDA beat our estimates by 3% each and PAT by 8%. EBITDA and PAT were 13% and 24% better than consensus estimates. Contribution from gRevlimid in the US helped the upside, though with strong support from all other businesses. We estimate ~USD 80mn of gRevlimid sales in the quarter. Exceptionally strong guidance More surprising than Q4 show was the exceptionally strong ...
Buy Zydus Lifesciences Ltd.For Target Rs. 1,321 - Elara Capital
Zydus Lifesciences is currently trading at Rs. 1103.45, up by 13.15 points or 1.21% from its previous closing of Rs. 1090.30 on the BSE. The scrip opened at Rs. 1095.20 and has touched a high and low of Rs. 1109.70 and Rs. 1093.80 respectively. So far 112109 shares were traded on the counter. The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 1171.95 on 21-May-2024 and a 52 week low of Rs. 533.10 on 15-Jun-2023. Last one week high and low of the scr...
Zydus Lifesciences jumps on getting USFDA`s tentative nod for Azilsartan Medoxomil and Chlorthalidone Tablets
Zydus Lifesciences is currently trading at Rs. 1024.20, up by 15.50 points or 1.54% from its previous closing of Rs. 1008.70 on the BSE. The scrip opened at Rs. 1016.05 and has touched a high and low of Rs. 1026.05 and Rs. 1011.00 respectively. So far 5360 shares were traded on the counter. The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 1033.15 on 07-May-2024 and a 52 week low of Rs. 482.55 on 22-May-2023. Last one week high and low of the scrip...
Zydus Lifesciences surges as its arm signs exclusive licensing, supply agreement with MSN Laboratories
Zydus Lifesciences is currently trading at Rs. 960.45, up by 1.00 points or 0.10% from its previous closing of Rs. 959.45 on the BSE. The scrip opened at Rs. 960.55 and has touched a high and low of Rs. 965.00 and Rs. 945.05 respectively. So far 26965 shares were traded on the counter. The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 1031.30 on 01-Apr-2024 and a 52 week low of Rs. 482.55 on 22-May-2023. Last one week high and low of the scrip stoo...
Zydus Lifesciences edges higher on getting nod for new drug application of Desidustat Tablets
Zydus Lifesciences is currently trading at Rs. 940.00, up by 17.80 points or 1.93% from its previous closing of Rs. 922.20 on the BSE. The scrip opened at Rs. 935.15 and has touched a high and low of Rs. 950.30 and Rs. 935.15 respectively. So far 969 shares were traded on the counter. The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 1031.30 on 01-Apr-2024 and a 52 week low of Rs. 482.55 on 22-May-2023. Last one week high and low of the scrip stood...
Zydus Lifesciences surges on launching Mirabegron Extended-Release tablets in US market
Zydus Lifesciences is currently trading at Rs. 1020.35, up by 20.85 points or 2.09% from its previous closing of Rs. 999.50 on the BSE. The scrip opened at Rs. 1009.70 and has touched a high and low of Rs. 1028.45 and Rs. 995.15 respectively. So far 62307 shares were traded on the counter. The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 1028.45 on 26-Mar-2024 and a 52 week low of Rs. 471.10 on 27-Mar-2023. Last one week high and low of the scrip ...
Zydus Lifesciences climbs on getting USFDA`s tentative approval for Letermovir Tablets
Zydus Lifesciences is currently trading at Rs. 990.40, up by 21.70 points or 2.24% from its previous closing of Rs. 968.70 on the BSE. The scrip opened at Rs. 969.05 and has touched a high and low of Rs. 999.70 and Rs. 961.85 respectively. So far 35265 shares were traded on the counter. The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 1015.70 on 11-Mar-2024 and a 52 week low of Rs. 463.20 on 14-Mar-2023. Last one week high and low of the scrip sto...
Zydus Lifesciences jumps on getting USFDA`s final approval for Chlorpromazine Hydrochloride Injection, Single-Dose Vials
Zydus Lifesciences is currently trading at Rs. 1007.05, up by 30.25 points or 3.10% from its previous closing of Rs. 976.80 on the BSE. The scrip opened at Rs. 986.60 and has touched a high and low of Rs. 1015.70 and Rs. 980.00 respectively. So far 44133 shares were traded on the counter. The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 1015.70 on 11-Mar-2024 and a 52 week low of Rs. 461.50 on 13-Mar-2023. Last one week high and low of the scrip s...
Zydus Lifesciences trades higher on the BSE
Zydus Lifesciences (ZYDUSLIF) Q3 EBITDA of Rs10.8bn (up 27% YoY) was 5% above our estimate aided by higher GMs and domestic formulation. We believe that company’s steady domestic franchise, strong balance sheet and potential new launches in US will help negate pricing pressure and likely competition in some key products like gAsacol. Moreover, ZYDUSLIF is also working on robust pipeline of complex products including injectables, transdermals, NCE, biosimilars and vac...
Accumulate Zydus Lifesciences Ltd For Target Rs. 855 - Prabhudas Lilladher Pvt. Ltd.
Zydus Lifesciences is currently trading at Rs. 974.95, up by 12.90 points or 1.34% from its previous closing of Rs. 962.05 on the BSE. The scrip opened at Rs. 962.00 and has touched a high and low of Rs. 982.10 and Rs. 958.55 respectively. So far 94414 shares were traded on the counter. The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 964.50 on 06-Mar-2024 and a 52 week low of Rs. 461.50 on 13-Mar-2023. Last one week high and low of the scrip stoo...
Zydus Lifesciences trades higher on getting post application action letter for cGMP, PAI at Ahmedabad facility
U.S. drugmaker Eli Lilly expects to launch Mounjaro, its blockbuster diabetes drug and wildly popular obesity treatment, in India as early as next year after it clears an ongoing regulatory review, CEO David Ricks told Reuters on Wednesday. The market opportunity is huge in the world's most populous country, which has high obesity rates, especially among women, and the second-highest number of people with type-2 diabetes globally. Indian drugmakers are making their own versions of such...
Exclusive-Eli Lilly could launch obesity drug in India next year, CEO says
Zydus Lifesciences is currently trading at Rs. 930.90, up by 8.80 points or 0.95% from its previous closing of Rs. 922.10 on the BSE. The scrip opened at Rs. 934.55 and has touched a high and low of Rs. 934.55 and Rs. 922.85 respectively. So far 7505 shares were traded on the counter. The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 937.00 on 23-Feb-2024 and a 52 week low of Rs. 452.20 on 27-Feb-2023. Last one week high and low of the scrip stood ...
Zydus Lifesciences gains on getting WHO prequalification approval for Miltefosine formulation, API
Zydus Lifesciences is currently trading at Rs. 910.90, up by 6.10 points or 0.67% from its previous closing of Rs. 904.80 on the BSE. The scrip opened at Rs. 892.60 and has touched a high and low of Rs. 911.75 and Rs. 892.60 respectively. So far 17555 shares were traded on the counter. The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 916.60 on 23-Feb-2024 and a 52 week low of Rs. 452.20 on 27-Feb-2023. Last one week high and low of the scrip stood...
Zydus Lifesciences gains on incorporating wholly owned subsidiary in UAE
Zydus Lifesciences (ZYDUSLIF) Q3 EBITDA of Rs10.8bn (up 27% YoY) was 5% above our estimate aided by higher GMs and domestic formulation. We believe that company’s steady domestic franchise, strong balance sheet and potential new launches in US will help negate pricing pressure and likely competition in some key products like gAsacol. Moreover, ZYDUSLIF is also working on robust pipeline of complex products including injectables, transdermals, NCE, biosimilars and vac...
Accumulate Zydus Lifesciences Ltd Target Rs. 855 - Prabhudas Liladhar Ltd
India/US/EM drives earnings Work in progress for innovative pipeline * Zydus Life sciences (ZYDUSLIF) delivered better-than-expected performance for 3QFY24. ZYDUSLIF exhibited superior execution in the domestic formulation (DF) and emerging markets; however, this was partly offset by a subdued performance in the API segment for the quarter. * We raise our earnings estimate by 6%/7% for FY24/FY25 to factor in a) the extended limited competition for g-Asacol, b) DF growth surpassing in...
Buy Zydus LifeSciences For Target Rs.820 - Motilal Oswal Financial Services Ltd
Indian generic drugmaker Zydus Lifesciences reported a bigger-than-expected rise in third-quarter profit on Friday, driven by strong sales in its domestic and overseas markets. Consolidated net profit for the company rose 27% to 7.90 billion rupees (about $95 million) for the three months ended Dec. 31, beating analysts' average estimate of 6.83 billion rupees, as per LSEG data. Separately, Zydus Lifesciences approved the buyback of shares worth six billion rupees via tender offer r...
India`s Zydus Lifesciences beats Q3 profit estimates; approves shares buyback
Zydus Lifesciences is currently trading at Rs. 808.40, up by 6.55 points or 0.82% from its previous closing of Rs. 801.85 on the BSE. The scrip opened at Rs. 805.00 and has touched a high and low of Rs. 809.85 and Rs. 802.00 respectively. So far 2090 shares were traded on the counter. The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 809.85 on 09-Feb-2024 and a 52 week low of Rs. 452.20 on 27-Feb-2023. Last one week high and low of the scrip stood ...
Zydus Lifesciences rises on getting final nods for Dexamethasone Tablets
Zydus Lifesciences is currently trading at Rs. 757.00, up by 8.15 points or 1.09% from its previous closing of Rs. 748.85 on the BSE. The scrip opened at Rs. 749.15 and has touched a high and low of Rs. 760.00 and Rs. 749.15 respectively. So far 20828 shares were traded on the counter. The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 760.00 on 30-Jan-2024 and a 52 week low of Rs. 425.05 on 03-Feb-2023. Last one week high and low of the scrip stood...
Zydus Lifesciences surges on launching Relugolix
Zydus Lifesciences is currently trading at Rs. 710.85, up by 2.00 points or 0.28% from its previous closing of Rs. 708.85 on the BSE. The scrip opened at Rs. 711.05 and has touched a high and low of Rs. 726.65 and Rs. 710.70 respectively. So far 11645 shares were traded on the counter. The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 726.65 on 19-Jan-2024 and a 52 week low of Rs. 421.50 on 27-Jan-2023. Last one week high and low of the scrip stood...
Zydus Lifesciences gains as its arm enters into licensing and supply agreement with Synthon BV
Zydus Lifesciences is currently trading at Rs. 674.90, up by 28.70 points or 4.44% from its previous closing of Rs. 646.20 on the BSE. The scrip opened at Rs. 650.40 and has touched a high and low of Rs. 677.25 and Rs. 650.40 respectively. So far 164482 shares were traded on the counter. The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 677.25 on 18-Dec-2023 and a 52 week low of Rs. 401.05 on 19-Dec-2022. Last one week high and low of the scrip sto...
Zydus Lifesciences moves higher on getting USFDA`s nod to initiate Phase II clinical study of`ZYIL1` in patients
Zydus Lifesciences is currently trading at Rs. 648.90, up by 5.40 points or 0.84% from its previous closing of Rs. 643.50 on the BSE. The scrip opened at Rs. 651.05 and has touched a high and low of Rs. 651.05 and Rs. 645.95 respectively. So far 1340 shares were traded on the counter. The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 668.50 on 10-Aug-2023 and a 52 week low of Rs. 401.05 on 19-Dec-2022. Last one week high and low of the scrip stood ...
Zydus Lifesciences rises on getting USFDA`s final approval for Darunavir Tablets 600 mg, 800 mg
Zydus Lifesciences is currently trading at Rs. 636.30, up by 2.80 points or 0.44% from its previous closing of Rs. 633.50 on the BSE. The scrip opened at Rs. 636.00 and has touched a high and low of Rs. 644.15 and Rs. 634.75 respectively. So far 13450 shares were traded on the counter. The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 668.50 on 10-Aug-2023 and a 52 week low of Rs. 401.05 on 19-Dec-2022. Last one week high and low of the scrip stood...
Zydus Lifesciences surges on getting USFDA`s final approval for Methylene Blue Injection
Zydus Lifesciences is currently trading at Rs. 639.65, up by 1.80 points or 0.28% from its previous closing of Rs. 637.85 on the BSE. The scrip opened at Rs. 640.00 and has touched a high and low of Rs. 648.70 and Rs. 639.65 respectively. So far 26027 shares were traded on the counter. The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 668.50 on 10-Aug-2023 and a 52 week low of Rs. 401.05 on 19-Dec-2022. Last one week high and low of the scrip stood...
Zydus Lifesciences gains on getting USFDA`s final approval for Ivabradine Tablets
ZYDUSLIF reported a robust EBITDAM of 26.2% despite no gRevlimid contribution. The company’s near-term launch pipeline remains attractive with a few niche launches, two transdermal launches, one REMS, gVascepa (3Q) and the Sitagliptin franchise. It plans to launch ~30 products annually with one exclusivity product in each of FY25/26/27. The LiqMeds acquisition is attractive as it provides access to specialty assets in UK/ US and is also EPS accretive. These initiatives will cumulatively...
Buy Zydus Lifesciences Ltd For Target Rs.720 - JM Financial Services
Indian generic drugmaker Zydus Lifesciences Ltd reported a better-than-expected 53.3% jump in quarterly profit on Tuesday, led by the strong sales in the domestic market and the United States. Consolidated net profit was 8.01 billion rupees ($96.2 million) in the quarter ended Sept 30, compared with 5.23 billion rupees a year earlier. Analysts, on an average, expected a profit of 7.58 billion rupees, per LSEG data. Total revenue from operations rose 9.1% to 43.69 billion rupees, boosted...
India`s Zydus Q2 profit jumps on strong domestic, US demand
Zydus Lifesciences is currently trading at Rs. 589.45, up by 4.85 points or 0.83% from its previous closing of Rs. 584.60 on the BSE. The scrip opened at Rs. 585.05 and has touched a high and low of Rs. 591.05 and Rs. 585.05 respectively. So far 562 shares were traded on the counter. The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 668.50 on 10-Aug-2023 and a 52 week low of Rs. 390.10 on 22-Nov-2022. Last one week high and low of the scrip stood a...
Zydus Lifesciences moves up on getting USFDA`s approval for ZITUVIMET
Zydus Lifesciences is currently trading at Rs. 577.30, up by 2.00 points or 0.35% from its previous closing of Rs. 575.30 on the BSE. The scrip opened at Rs. 578.30 and has touched a high and low of Rs. 580.65 and Rs. 571.65 respectively. So far 3076 shares were traded on the counter. The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 668.50 on 10-Aug-2023 and a 52 week low of Rs. 390.10 on 22-Nov-2022. Last one week high and low of the scrip stood ...
Zydus Lifesciences rises on signing co-marketing agreement with Guardant Health
Zydus Lifesciences is currently trading at Rs. 574.85, up by 1.05 points or 0.18% from its previous closing of Rs. 573.80 on the BSE. The scrip opened at Rs. 580.60 and has touched a high and low of Rs. 580.60 and Rs. 571.00 respectively. So far 8457 shares were traded on the counter. The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 668.50 on 10-Aug-2023 and a 52 week low of Rs. 390.10 on 22-Nov-2022. Last one week high and low of the scrip stood ...
Zydus Lifesciences moves up as its arm acquires UK based LiqMeds Group
Zydus Lifesciences is currently trading at Rs. 579.85, up by 5.05 points or 0.88% from its previous closing of Rs. 574.80 on the BSE. The scrip opened at Rs. 577.15 and has touched a high and low of Rs. 582.30 and Rs. 574.50 respectively. So far 6464 shares were traded on the counter. The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 668.50 on 10-Aug-2023 and a 52 week low of Rs. 390.10 on 22-Nov-2022. Last one week high and low of the scrip stood ...
Zydus Lifesciences surges on signing licensing agreement with Sun Pharma for co-marketing of Desidustat
Zydus Lifesciences is currently trading at Rs. 581.10, up by 2.55 points or 0.44% from its previous closing of Rs. 578.55 on the BSE.The scrip opened at Rs. 578.60 and has touched a high and low of Rs. 589.15 and Rs. 578.60 respectively. So far 2305 shares were traded on the counter.The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 668.50 on 10-Aug-2023 and a 52 week low of Rs. 390.10 on 22-Nov-2022.Last one week high and low of the scrip stood at Rs. 597.30 and Rs...
Zydus Lifesciences shines on getting USFDA`s approval for ZITUVIO tablets
Zydus Lifesciences is currently trading at Rs. 630.50, up by 6.00 points or 0.96% from its previous closing of Rs. 624.50 on the BSE.The scrip opened at Rs. 628.35 and has touched a high and low of Rs. 630.95 and Rs. 628.15 respectively. So far 1387 shares were traded on the counter.The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 668.50 on 10-Aug-2023 and a 52 week low of Rs. 350.30 on 26-Sep-2022.Last one week high and low of the scrip stood at Rs. 653.55 and Rs...
Zydus Lifesciences rises on getting final nod for Clindamycin Phosphate Gel
Zydus Lifesciences is currently trading at Rs. 643.90, up by 4.20 points or 0.66% from its previous closing of Rs. 639.70 on the BSE.The scrip opened at Rs. 641.80 and has touched a high and low of Rs. 647.30 and Rs. 641.00 respectively. So far 12530 shares were traded on the counter.The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 668.50 on 10-Aug-2023 and a 52 week low of Rs. 350.30 on 26-Sep-2022.Last one week high and low of the scrip stood at Rs. 649.40 and R...
Zydus Lifesciences surges on getting USFDA`s final approval for Norelgestromin and Ethinyl Estradiol Transdermal System
Zydus Lifesciences is currently trading at Rs. 628.75, up by 0.05 points or 0.01% from its previous closing of Rs. 628.70 on the BSE.The scrip opened at Rs. 626.45 and has touched a high and low of Rs. 642.85 and Rs. 624.15 respectively. So far 66169 shares were traded on the counter.The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 668.50 on 10-Aug-2023 and a 52 week low of Rs. 350.30 on 26-Sep-2022.Last one week high and low of the scrip stood at Rs. 644.20 and R...
Zydus Lifesciences inches up in volatile trade
Load More
